The U.S. Food and Drug Administration issued a Warning Letter to Novo Nordisk Inc. following an inspection conducted under the Bioresearch Monitoring Program.
The inspection identified serious and systemic violations of postmarketing adverse drug experience (PADE) reporting requirements.
Lessons learnt from this warning letter:
1. Inadequate Pharmacovigilance (PV) Procedures
- Failure to establish robust written procedures for surveillance, receipt, evaluation, and reporting of adverse drug experiences (ADEs).
- SOPs allowed exclusion of ADEs based on lack of causality, which is non-compliant with FDA regulations requiring reporting regardless of relatedness.
2. Failure to Submit 15-Day Alert Reports
- Serious and unexpected ADEs were:
- Result: Multiple cases were not reported within the required 15-day timeframe.
3. Deficiencies in Case Processing and Vendor Oversight
- Ineffective oversight of third-party call center vendors led to:
- Corrective actions (e.g., vendor changes, training) were not effectively implemented.
4. Failure to Promptly Investigate ADEs
- SOPs required patient consent for follow-up, which is not mandated by FDA regulations.
- Resulted in:
- Lack of follow-up investigations, even in serious cases (e.g., death, suicide)
- Closure of cases without submission to FDA
5. Ineffective CAPA and Root Cause Analysis
- Deviations were identified but:
- Root causes were not adequately addressed
- Corrective and preventive actions (CAPAs) lacked effectiveness
- FDA could not verify whether all impacted cases were eventually reported
Final Takeaway
These violations reflect not just simple lack of understanding of patient centric pharmacovigilance monitoring systems but also lack of education and training in implementing necessary reporting obligations from MAHs.
Even though Most PV violations don’t happen due to lack of knowledge—they happen due to gaps in execution, oversight, and accountability.
A compliant PV system is one where:
- Processes are clear with SOPs and WIs
- People are trained and knowledgeable in PV
- Systems are monitored with KPIs
- Leadership is involved
Here is the link for the actual warning letter from FDA - https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/novo-nordisk-inc-717576-03052026
No Comments